Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eluxadoline 5 mg | Experimental | Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks. |
|
| Eluxadoline 25 mg | Experimental | Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. . |
|
| Eluxadoline 100 mg | Experimental | Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks. |
|
| Eluxadoline 200 mg | Experimental | Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. |
|
| Placebo | Placebo Comparator | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Eluxadoline | Drug | Tablets, orally, twice daily. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4 | Composite responders were defined as participants who completed at least 5 out of 7 days with diary entries during the interval of interest and met both of the following criteria: 1) Average daily pain response scores over the past week improved by ≥30% and at least 2 points as compared with the baseline average pain score (average of daily worst abdominal pain the week prior to randomization), 2) Bristol Stool Scale (BSS) score of 3 or 4 on 66% of reported days in the past week. Abdominal pain was assessed on an 11-point scale where: 0=no pain to 10=worst pain imaginable. Stool consistency was assessed using the BSS 7-point scale where: 1=separate hard lumps, 2=sausage shaped but lumpy, 3=sausage-like with cracks on the surface, 4=sausage-like but smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, and 7=watery with no solid pieces. | Baseline (Week prior to Randomization) to Week 4 |
| Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 12 | Composite responders were defined as participants who completed at least 5 out of 7 days with diary entries during the interval of interest and met both of the following criteria: 1) Average daily pain response scores over the past week improved by ≥30% and at least 2 points as compared with the baseline average pain score (average of daily worst abdominal pain the week prior to randomization), 2) Bristol Stool Scale (BSS) score of 3 or 4 on 66% of reported days in the past week. The participant recorded their abdominal pain in a daily diary using an 11-point scale where: 0=no pain to 10=worst pain imaginable. The participant recorded stool consistency in a daily diary using the BSS 7-point scale where: 1=separate hard lumps, 2=sausage shaped but lumpy, 3=sausage-like with cracks on the surface, 4=sausage-like but smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, and 7=watery with no solid pieces. | Baseline (Week prior to Randomization) to Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the Weekly Pain Scores | The participant recorded their worst daily pain score in a diary using an 11-point scale where: 0=no pain to 10=worst pain imaginable. The daily scores over the previous week were averaged. A negative change from Baseline indicates improvement. | Baseline (Week Prior to Randomization) to Weeks 4, 8, and 12 |
Not provided
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-specific eligibility criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Furiex Research Site | Anniston | Alabama | 36207 | United States | ||
| Furiex Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28167156 | Derived | Fant RV, Henningfield JE, Cash BD, Dove LS, Covington PS. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3. | |
| 24813429 | Derived |
Not provided
Not provided
807 patients were randomized in the trial. 18 of these patients were enrolled at a site terminated by Furiex, reported to the FDA for potential scientific misconduct, and were excluded from all datasets. All Randomized Patients=789 patients.
9 patients were randomized more than once, enrolling at a second (or third) site after discontinuation from the first site. Safety data was analyzed according to the highest dose received. Safety Analysis Set: Highest Dose Level in the Participant Flow reflects the reassignment of patients randomized more than once to the highest dose level arm.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Eluxadoline 5 mg | Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks. |
| FG001 | Eluxadoline 25 mg | Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Matching placebo oral tablets twice daily. |
|
| Change From Baseline in Weekly BSS Scores | The patient recorded stool consistency in a daily diary using the BSS 7-point scale where: 1=hard stool to 7=watery diarrhea. The daily scores over the previous week were averaged. A negative change from Baseline indicates improvement. | Baseline (Week prior to Randomization) to Weeks 4, 8, and 12 |
| Change From Baseline in the Number of Daily Bowel Movements | Participants recorded the number of bowel movements in a daily diary at the same time each day. The number of daily bowel movements over the previous week were averaged. A negative change from Baseline indicates improvement. | Baseline (Week prior to Randomization) to Weeks 4, 8, and 12 |
| Percentage of Participants With Response Based on Participants Achieving Prespecified Improvement in Symptoms for at Least 50% of the Time | Responders were participants that met both of the following criteria on the same week for at least 50% of time on study: 1) average of daily pain scores over the past week improved by ≥30% compared with baseline average in pain score, 2) ≥50% reduction in the number of days over the past week with a BSS score ≥5 compared with Baseline. Participants must also have had at least 5/7 days diary entry to be considered a responder for that week. Abdominal pain was assessed on an 11-point scale where a score of 0=no pain to 10=worst pain imaginable. Stool consistency was assessed using the BSS 7-point scale where: 1=separate hard lumps to 7=watery with no solid pieces. Response rates (percentage of participants) are based on model estimates from the logistic regression. | Baseline (Week Prior to Randomization) to Weeks 1-12 |
| Birmingham |
| Alabama |
| 35216 |
| United States |
| Furiex Research Site | Birmingham | Alabama | 35235 | United States |
| Furiex Research Site | Dothan | Alabama | 36305 | United States |
| Furiex Research Site | Huntsville | Alabama | 35801 | United States |
| Furiex Research Site | Huntsville | Alabama | 35802 | United States |
| Furiex Research Site | Mobile | Alabama | 36693 | United States |
| Furiex Research Site | Montgomery | Alabama | 36109 | United States |
| Furiex Research Site | Pell City | Alabama | 35128 | United States |
| Furiex Research Site | Chandler | Arizona | 85224 | United States |
| Furiex Research Site | Glendale | Arizona | 85308 | United States |
| Furiex Research Site | Mesa | Arizona | 85203 | United States |
| Furiex Research Site | Phoenix | Arizona | 85018 | United States |
| Furiex Research Site | Phoenix | Arizona | 85020 | United States |
| Furiex Research Site | Phoenix | Arizona | 85050 | United States |
| Furiex Research Site | Tempe | Arizona | 85282 | United States |
| Furiex Research Site | Tempe | Arizona | 85283 | United States |
| Furiex Research Site | Tucson | Arizona | 85704 | United States |
| Furiex Research Site | Tucson | Arizona | 85710 | United States |
| Furiex Research Site | Jonesboro | Arkansas | 72401 | United States |
| Furiex Research Site | Little Rock | Arkansas | 72211 | United States |
| Furiex Research Site | Searcy | Arkansas | 72143 | United States |
| Furiex Research Site | Sherwood | Arkansas | 72120 | United States |
| Furiex Research Site | Aliso Viejo | California | 92656 | United States |
| Furiex Research Site | Anaheim | California | 92801 | United States |
| Furiex Research Site | Azusa | California | 91702 | United States |
| Furiex Research Site | Burbank | California | 91505 | United States |
| Furiex Research Site | Carlsbad | California | 92008 | United States |
| Furiex Research Site | Encinitas | California | 92024 | United States |
| Furiex Research Site | Garden Grove | California | 92840 | United States |
| Furiex Research Site | Garden Grove | California | 92843 | United States |
| Furiex Research Site | Inglewood | California | 90301 | United States |
| Furiex Research Site | Laguna Hills | California | 92653 | United States |
| Furiex Research Site | Long Beach | California | 90806 | United States |
| Furiex Research Site | Los Angeles | California | 90015 | United States |
| Furiex Research Site | Los Angeles | California | 90045 | United States |
| Furiex Research Site | Murrieta | California | 92562 | United States |
| Furiex Research Site | Oakland | California | 94609 | United States |
| Furiex Research Site | Orange | California | 92869 | United States |
| Furiex Research Site | Sacramento | California | 95825 | United States |
| Furiex Research Site | San Carlos | California | 94070 | United States |
| Furiex Research Site | San Diego | California | 92103-6204 | United States |
| Furiex Research Site | San Diego | California | 92120 | United States |
| Furiex Research Site | Colorado Springs | Colorado | 80904 | United States |
| Furiex Research Site | Colorado Springs | Colorado | 80907 | United States |
| Furiex Research Site | Colorado Springs | Colorado | 80920 | United States |
| Furiex Research Site | Colorado Springs | Colorado | 80922 | United States |
| Furiex Research Site | Denver | Colorado | 80222 | United States |
| Furiex Research Site | Denver | Colorado | 80239 | United States |
| Furiex Research Site | Lakewood | Colorado | 80215 | United States |
| Furiex Research Site | Littleton | Colorado | 80120 | United States |
| Furiex Research Site | Thornton | Colorado | 80229 | United States |
| Furiex Research Site | Bristol | Connecticut | 06010 | United States |
| Furiex Research Site | Waterbury | Connecticut | 06708 | United States |
| Furiex Research Site | Aventura | Florida | 33916 | United States |
| Furiex Research Site | Boca Raton | Florida | 33428 | United States |
| Furiex Research Site | Boca Raton | Florida | 33432 | United States |
| Furiex Research Site | Bradenton | Florida | 34208 | United States |
| Furiex Research Site | Brandon | Florida | 33511 | United States |
| Furiex Research Site | Chipley | Florida | 32428 | United States |
| Furiex Research Site | DeLand | Florida | 32720 | United States |
| Furiex Research Site | Delray Beach | Florida | 33484 | United States |
| Furiex Research Site | Doral | Florida | 33172 | United States |
| Furiex Research Site | Fort Lauderdale | Florida | 33306 | United States |
| Furiex Research Site | Hialeah | Florida | 33013 | United States |
| Furiex Research Site | Hialeah | Florida | 33016 | United States |
| Furiex Research Site | Inverness | Florida | 34452 | United States |
| Furiex Research Site | Jacksonville | Florida | 32209 | United States |
| Furiex Research Site | Jacksonville | Florida | 32256 | United States |
| Furiex Research Site | Jupiter | Florida | 33458 | United States |
| Furiex Research Site | Kissimmee | Florida | 34741 | United States |
| Furiex Research Site | Largo | Florida | 33777 | United States |
| Furiex Research Site | Lauderdale Lakes | Florida | 33319 | United States |
| Furiex Research Site | Melbourne | Florida | 32935 | United States |
| Furiex Research Site | Miami | Florida | 33126 | United States |
| Furiex Research Site | Miami | Florida | 33135 | United States |
| Furiex Research Site | Miami | Florida | 33155 | United States |
| Furiex Research Site | Naples | Florida | 34102 | United States |
| Furiex Research Site | Naples | Florida | 34109 | United States |
| Furiex Research Site | New Port Richey | Florida | 34652 | United States |
| Furiex Research Site | New Port Richey | Florida | 34655 | United States |
| Furiex Research Site | New Smyrna Beach | Florida | 32168 | United States |
| Furiex Research Site | Orlando | Florida | 32837 | United States |
| Furiex Research Site | Plantation | Florida | 33317 | United States |
| Furiex Research Site | Port Orange | Florida | 32129 | United States |
| Furiex Research Site | South Miami | Florida | 33143 | United States |
| Furiex Research Site | St. Petersburg | Florida | 33709 | United States |
| Furiex Research Site | Tampa | Florida | 33606 | United States |
| Furiex Research Site | Tampa | Florida | 33613 | United States |
| Furiex Research Site | Atlanta | Georgia | 30312 | United States |
| Furiex Research Site | Atlanta | Georgia | 30338 | United States |
| Furiex Research Site | Columbus | Georgia | 31904 | United States |
| Furiex Research Site | Duluth | Georgia | 30096 | United States |
| Furiex Research Site | Macon | Georgia | 31201 | United States |
| Furiex Research Site | Marietta | Georgia | 30066 | United States |
| Furiex Research Site | Newnan | Georgia | 30263 | United States |
| Furiex Research Site | Rome | Georgia | 30165 | United States |
| Furiex Research Site | Sandy Springs | Georgia | 30328 | United States |
| Furiex Research Site | Savannah | Georgia | 31406 | United States |
| Furiex Research Site | Boise | Idaho | 83702 | United States |
| Furiex Research Site | Boise | Idaho | 83704 | United States |
| Furiex Research Site | Idaho Falls | Idaho | 83404 | United States |
| Furiex Research Site | Meridian | Idaho | 83642 | United States |
| Furiex Research Site | Nampa | Idaho | 83686 | United States |
| Furiex Research Site | Champaign | Illinois | 61820 | United States |
| Furiex Research Site | Chicago | Illinois | 60634 | United States |
| Furiex Research Site | Morton | Illinois | 61550 | United States |
| Furiex Research Site | Anderson | Indiana | 46016 | United States |
| Furiex Research Site | Bloomington | Indiana | 47403 | United States |
| Furiex Research Site | Evansville | Indiana | 47714 | United States |
| Furiex Research Site | Indianapolis | Indiana | 46205 | United States |
| Furiex Research Site | Indianapolis | Indiana | 46237 | United States |
| Furiex Research Site | Indianapolis | Indiana | 46250 | United States |
| Furiex Research Site | Lenexa | Kansas | 66215 | United States |
| Furiex Research Site | Mission | Kansas | 66202 | United States |
| Furiex Research Site | Overland Park | Kansas | 66202 | United States |
| Furiex Research Site | Overland Park | Kansas | 66215 | United States |
| Furiex Research Site | Topeka | Kansas | 66606 | United States |
| Furiex Research Site | Wichita | Kansas | 67203 | United States |
| Furiex Research Site | Bowling Green | Kentucky | 42101 | United States |
| Furiex Research Site | Lexington | Kentucky | 40504 | United States |
| Furiex Research Site | Louisville | Kentucky | 40202 | United States |
| Furiex Research Site | Metairie | Louisiana | 70006 | United States |
| Furiex Research Site | Monroe | Louisiana | 71201 | United States |
| Furiex Research Site | Opelousas | Louisiana | 70570 | United States |
| Furiex Research Site | Shreveport | Louisiana | 71101 | United States |
| Furiex Research Site | Shreveport | Louisiana | 71103 | United States |
| Furiex Research Site | Annapolis | Maryland | 21401 | United States |
| Furiex Research Site | Chevy Chase | Maryland | 20815 | United States |
| Furiex Research Site | Hollywood | Maryland | 20636 | United States |
| Furiex Research Site | Laurel | Maryland | 20707 | United States |
| Furiex Research Site | Lutherville | Maryland | 21093 | United States |
| Furiex Research Site | Prince Frederick | Maryland | 20678 | United States |
| Furiex Research Site | Rockville | Maryland | 20850 | United States |
| Furiex Research Site | Boston | Massachusetts | 02114 | United States |
| Furiex Research Site | Boston | Massachusetts | 02135 | United States |
| Furiex Research Site | Boston | Massachusetts | 02215 | United States |
| Furiex Research Site | Brockton | Massachusetts | 02301 | United States |
| Furiex Research Site | Hyannis | Massachusetts | 02601 | United States |
| Furiex Research Site | Springfield | Massachusetts | 01105 | United States |
| Furiex Research Site | Chesterfield | Michigan | 48047 | United States |
| Furiex Research Site | Interlochen | Michigan | 49643 | United States |
| Furiex Research Site | Kalamazoo | Michigan | 49009 | United States |
| Furiex Research Site | Novi | Michigan | 48377 | United States |
| Furiex Research Site | Troy | Michigan | 48098 | United States |
| Furiex Research Site | Chaska | Minnesota | 55318 | United States |
| Furiex Research Site | Jackson | Mississippi | 39202 | United States |
| Furiex Research Site | Tupelo | Mississippi | 38801 | United States |
| Furiex Research Site | City of Saint Peters | Missouri | 63376 | United States |
| Furiex Research Site | Mexico | Missouri | 65265 | United States |
| Furiex Research Site | St Louis | Missouri | 63141 | United States |
| Furiex Research Site | Billings | Montana | 59102 | United States |
| Furiex Research Site | Bozeman | Montana | 59718 | United States |
| Furiex Research Site | Bellevue | Nebraska | 68005 | United States |
| Furiex Research Site | Omaha | Nebraska | 68114 | United States |
| Furiex Research Site | Omaha | Nebraska | 68144 | United States |
| Furiex Research Site | Henderson | Nevada | 89052 | United States |
| Furiex Research Site | Las Vegas | Nevada | 89106 | United States |
| Furiex Research Site | Las Vegas | Nevada | 89183 | United States |
| Furiex Research Site | Atco | New Jersey | 08044 | United States |
| Furiex Research Site | Blackwood | New Jersey | 08012 | United States |
| Furiex Research Site | Elizabeth | New Jersey | 07202 | United States |
| Furiex Research Site | Marlton | New Jersey | 08053 | United States |
| Furiex Research Site | Morristown | New Jersey | 07960 | United States |
| Furiex Research Site | South Bound Brook | New Jersey | 08880 | United States |
| Furiex Research Site | Vineland | New Jersey | 08360 | United States |
| Furiex Research Site | Albuquerque | New Mexico | 87102 | United States |
| Furiex Research Site | Albuquerque | New Mexico | 87108 | United States |
| Furiex Research Site | Binghamton | New York | 13903 | United States |
| Furiex Research Site | Brooklyn | New York | 11214 | United States |
| Furiex Research Site | Brooklyn | New York | 11230 | United States |
| Furiex Research Site | Great Neck | New York | 11021 | United States |
| Furiex Research Site | Great Neck | New York | 11023 | United States |
| Furiex Research Site | Mineola | New York | 11501 | United States |
| Furiex Research Site | New York | New York | 10016 | United States |
| Furiex Research Site | Boone | North Carolina | 28607 | United States |
| Furiex Research Site | Chapel Hill | North Carolina | 27599 | United States |
| Furiex Research Site | Charlotte | North Carolina | 28209 | United States |
| Furiex Research Site | Charlotte | North Carolina | 28277 | United States |
| Furiex Research Site | Fayetteville | North Carolina | 28304 | United States |
| Furiex Research Site | Greensboro | North Carolina | 27401 | United States |
| Furiex Research Site | Greensboro | North Carolina | 27403 | United States |
| Furiex Research Site | Greenville | North Carolina | 27834 | United States |
| Furiex Research Site | Harrisburg | North Carolina | 28075 | United States |
| Furiex Research Site | Hickory | North Carolina | 28601 | United States |
| Furiex Research Site | Hickory | North Carolina | 28602 | United States |
| Furiex Research Site | High Point | North Carolina | 27262 | United States |
| Furiex Research Site | Jacksonville | North Carolina | 28546 | United States |
| Furiex Research Site | New Bern | North Carolina | 28562 | United States |
| Furiex Research Site | Raleigh | North Carolina | 27609 | United States |
| Furiex Research Site | Raleigh | North Carolina | 27612 | United States |
| Furiex Research Site | Wilmington | North Carolina | 28401 | United States |
| Furiex Research Site | Winston-Salem | North Carolina | 27103-3914 | United States |
| Furiex Research Site | Winston-Salem | North Carolina | 27103 | United States |
| Furiex Research Site | Fargo | North Dakota | 58103 | United States |
| Furiex Research Site | Fargo | North Dakota | 58104 | United States |
| Furiex Research Site | Akron | Ohio | 44302 | United States |
| Furiex Research Site | Beachwood | Ohio | 44122 | United States |
| Furiex Research Site | Beavercreek | Ohio | 45432 | United States |
| Furiex Research Site | Cincinnati | Ohio | 45229 | United States |
| Furiex Research Site | Cleveland | Ohio | 44122 | United States |
| Furiex Research Site | Columbus | Ohio | 43214 | United States |
| Furiex Research Site | Columbus | Ohio | 43215 | United States |
| Furiex Research Site | Dayton | Ohio | 45432 | United States |
| Furiex Research Site | Franklin | Ohio | 45005 | United States |
| Furiex Research Site | Mentor | Ohio | 44060 | United States |
| Furiex Research Site | Miamisburg | Ohio | 45342-3705 | United States |
| Furiex Research Site | Springfield | Ohio | 45504 | United States |
| Furiex Research Site | Wadsworth | Ohio | 44281 | United States |
| Furiex Research Site | Norman | Oklahoma | 73069 | United States |
| Furiex Research Site | Norman | Oklahoma | 73071 | United States |
| Furiex Research Site | Oklahoma City | Oklahoma | 73104 | United States |
| Furiex Research Site | Oklahoma City | Oklahoma | 73112 | United States |
| Furiex Research Site | Yukon | Oklahoma | 73099 | United States |
| Furiex Research Site | Dingmans Ferry | Pennsylvania | 18328 | United States |
| Furiex Research Site | Hermitage | Pennsylvania | 16148 | United States |
| Furiex Research Site | Jenkintown | Pennsylvania | 19046 | United States |
| Furiex Research Site | Lancaster | Pennsylvania | 17604 | United States |
| Furiex Research Site | Lansdale | Pennsylvania | 19446 | United States |
| Furiex Research Site | Newton | Pennsylvania | 18940 | United States |
| Furiex Research Site | Sayre | Pennsylvania | 18840 | United States |
| Furiex Research Site | Uniontown | Pennsylvania | 15401 | United States |
| Furiex Research Site | Washington | Pennsylvania | 15301 | United States |
| Furiex Research Site | Cumberland | Rhode Island | 02864 | United States |
| Furiex Research Site | East Providence | Rhode Island | 02914 | United States |
| Furiex Research Site | Warwick | Rhode Island | 02886 | United States |
| Furiex Research Site | Anderson | South Carolina | 29621 | United States |
| Furiex Research Site | Columbia | South Carolina | 29201 | United States |
| Furiex Research Site | Columbia | South Carolina | 29203 | United States |
| Furiex Research Site | Greer | South Carolina | 29651 | United States |
| Furiex Research Site | Mt. Pleasant | South Carolina | 29464 | United States |
| Furiex Research Site | Rapid City | South Dakota | 57702 | United States |
| Furiex Research Site | Bristol | Tennessee | 37620 | United States |
| Furiex Research Site | Chattanooga | Tennessee | 37404 | United States |
| Furiex Research Site | Chattanooga | Tennessee | 37421 | United States |
| Furiex Research Site | Germantown | Tennessee | 38138 | United States |
| Furiex Research Site | Jackson | Tennessee | 38301 | United States |
| Furiex Research Site | Johnson City | Tennessee | 37604 | United States |
| Furiex Research Site | Kingsport | Tennessee | 37660 | United States |
| Furiex Research Site | Nashville | Tennessee | 37203 | United States |
| Furiex Research Site | Nashville | Tennessee | 37205 | United States |
| Furiex Research Site | Austin | Texas | 78705 | United States |
| Furiex Research Site | Bedford | Texas | 76022 | United States |
| Furiex Research Site | Colleyville | Texas | 76034 | United States |
| Furiex Research Site | El Paso | Texas | 79902 | United States |
| Furiex Research Site | Fort Worth | Texas | 76107 | United States |
| Furiex Research Site | Fort Worth | Texas | 76108 | United States |
| Furiex Research Site | Grand Prairie | Texas | 75052 | United States |
| Furiex Research Site | Grapevine | Texas | 76051 | United States |
| Furiex Research Site | Houston | Texas | 77005 | United States |
| Furiex Research Site | Houston | Texas | 77022 | United States |
| Furiex Research Site | Houston | Texas | 77030 | United States |
| Furiex Research Site | Houston | Texas | 77034 | United States |
| Furiex Research Site | Houston | Texas | 77074 | United States |
| Furiex Research Site | Houston | Texas | 77081 | United States |
| Furiex Research Site | Houston | Texas | 77090 | United States |
| Furiex Research Site | Houston | Texas | 77505 | United States |
| Furiex Research Site | Hurst | Texas | 76054 | United States |
| Furiex Research Site | Irving | Texas | 75061 | United States |
| Furiex Research Site | Lake Jackson | Texas | 77566 | United States |
| Furiex Research Site | Marshall | Texas | 75670 | United States |
| Furiex Research Site | North Richland Hills | Texas | 76180 | United States |
| Furiex Research Site | Odessa | Texas | 79761 | United States |
| Furiex Research Site | Plano | Texas | 75074 | United States |
| Furiex Research Site | San Antonio | Texas | 78209 | United States |
| Furiex Research Site | San Antonio | Texas | 78212 | United States |
| Furiex Research Site | San Antonio | Texas | 78215 | United States |
| Furiex Research Site | San Antonio | Texas | 78229 | United States |
| Furiex Research Site | San Antonio | Texas | 78258 | United States |
| Furiex Research Site | Sugar Land | Texas | 77478 | United States |
| Furiex Research Site | Sugar Land | Texas | 77479 | United States |
| Furiex Research Site | Webster | Texas | 77598 | United States |
| Furiex Research Site | Logan | Utah | 84341 | United States |
| Furiex Research Site | Ogden | Utah | 84405 | United States |
| Furiex Research Site | Salt Lake City | Utah | 84109 | United States |
| Furiex Research Site | Salt Lake City | Utah | 84121 | United States |
| Furiex Research Site | South Jordan | Utah | 84095 | United States |
| Furiex Research Site | West Jordan | Utah | 84088 | United States |
| Furiex Research Site | West Valley City | Utah | 84120 | United States |
| Furiex Research Site | Alexandria | Virginia | 22304 | United States |
| Furiex Research Site | Chesapeake | Virginia | 23320 | United States |
| Furiex Research Site | Christiansburg | Virginia | 24073 | United States |
| Furiex Research Site | Danville | Virginia | 24541 | United States |
| Furiex Research Site | Fairfax | Virginia | 22031 | United States |
| Furiex Research Site | Virginia Beach | Virginia | 23455 | United States |
| Furiex Research Site | Mill Creek | Washington | 98012-6316 | United States |
| Furiex Research Site | Madison | Wisconsin | 53715 | United States |
| Furiex Research Site | Milwaukee | Wisconsin | 53226 | United States |
| Andrae DA, Covington PS, Patrick DL. Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome. Clin Ther. 2014 May;36(5):663-79. doi: 10.1016/j.clinthera.2014.04.009. Epub 2014 May 9. |
| 23583433 | Derived | Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9. |
| FG002 | Eluxadoline 100 mg | Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks. |
| FG003 | Eluxadoline 200 mg | Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. |
| FG004 | Placebo | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. |
| Safety Analysis Set: as Randomized | All participants who received study drug as per randomized dose assignment. |
|
| Safety Analysis Set: Highest Dose Level | Reflects the reassignment of patients randomized more than once to the highest dose level arm. |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
All randomized patients.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Eluxadoline 5 mg | Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks. |
| BG001 | Eluxadoline 25 mg | Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. |
| BG002 | Eluxadoline 100 mg | Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks. |
| BG003 | Eluxadoline 200 mg | Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. |
| BG004 | Placebo | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. |
| BG005 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||
| Age, Customized | Number | Participants |
| |||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||
| Race/Ethnicity, Customized | Number | Participants |
| |||||||||||
| Race/Ethnicity, Customized | Number | Participants |
| |||||||||||
| Height | Mean | Standard Deviation | cm |
| ||||||||||
| Weight | Number analyzed is the number of participants with available weight data for analysis. | Mean | Standard Deviation | kg |
| |||||||||
| Body Mass Index (BMI) | Number analyzed is the number of participants with available BMI data for analysis. | Mean | Standard Deviation | kg/m^2 |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4 | Composite responders were defined as participants who completed at least 5 out of 7 days with diary entries during the interval of interest and met both of the following criteria: 1) Average daily pain response scores over the past week improved by ≥30% and at least 2 points as compared with the baseline average pain score (average of daily worst abdominal pain the week prior to randomization), 2) Bristol Stool Scale (BSS) score of 3 or 4 on 66% of reported days in the past week. Abdominal pain was assessed on an 11-point scale where: 0=no pain to 10=worst pain imaginable. Stool consistency was assessed using the BSS 7-point scale where: 1=separate hard lumps, 2=sausage shaped but lumpy, 3=sausage-like with cracks on the surface, 4=sausage-like but smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, and 7=watery with no solid pieces. | Intent to treat (ITT) set was defined as the 754 participants that received at least 1 dose of study drug and had baseline and at least 1 postrandomization daily pain rating and 1 postrandomization Bristol Stool Scale (BSS) rating. | Posted | Number | percentage of participants | Baseline (Week prior to Randomization) to Week 4 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 12 | Composite responders were defined as participants who completed at least 5 out of 7 days with diary entries during the interval of interest and met both of the following criteria: 1) Average daily pain response scores over the past week improved by ≥30% and at least 2 points as compared with the baseline average pain score (average of daily worst abdominal pain the week prior to randomization), 2) Bristol Stool Scale (BSS) score of 3 or 4 on 66% of reported days in the past week. The participant recorded their abdominal pain in a daily diary using an 11-point scale where: 0=no pain to 10=worst pain imaginable. The participant recorded stool consistency in a daily diary using the BSS 7-point scale where: 1=separate hard lumps, 2=sausage shaped but lumpy, 3=sausage-like with cracks on the surface, 4=sausage-like but smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, and 7=watery with no solid pieces. | ITT analysis set was defined as the 754 participants that received at least 1 dose of study drug and had baseline and at least 1 postrandomization daily pain rating and 1 postrandomization Bristol Stool Scale (BSS) rating. | Posted | Number | percentage of participants | Baseline (Week prior to Randomization) to Week 12 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Weekly Pain Scores | The participant recorded their worst daily pain score in a diary using an 11-point scale where: 0=no pain to 10=worst pain imaginable. The daily scores over the previous week were averaged. A negative change from Baseline indicates improvement. | ITT analysis set was defined as the 754 participants that received at least 1 dose of study drug and had baseline and at least 1 postrandomization daily pain rating and 1 postrandomization Bristol Stool Scale (BSS) rating. Number analyzed is the number of participants with data available at the given time-point. | Posted | Mean | Standard Deviation | scores on a scale | Baseline (Week Prior to Randomization) to Weeks 4, 8, and 12 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Weekly BSS Scores | The patient recorded stool consistency in a daily diary using the BSS 7-point scale where: 1=hard stool to 7=watery diarrhea. The daily scores over the previous week were averaged. A negative change from Baseline indicates improvement. | ITT analysis set was defined as the 754 participants that received at least 1 dose of study drug and had baseline and at least 1 postrandomization daily pain rating and 1 postrandomization Bristol Stool Scale (BSS) rating. Number analyzed is the number of participants with data available at the given time-point. | Posted | Mean | Standard Deviation | scores on a scale | Baseline (Week prior to Randomization) to Weeks 4, 8, and 12 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Number of Daily Bowel Movements | Participants recorded the number of bowel movements in a daily diary at the same time each day. The number of daily bowel movements over the previous week were averaged. A negative change from Baseline indicates improvement. | ITT analysis set was defined as the 754 participants that received at least 1 dose of study drug and had baseline and at least 1 postrandomization daily pain rating and 1 postrandomization Bristol Stool Scale (BSS) rating. Number analyzed is the number of participants with data available at the given time-point. | Posted | Mean | Standard Deviation | bowel movements per day | Baseline (Week prior to Randomization) to Weeks 4, 8, and 12 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Response Based on Participants Achieving Prespecified Improvement in Symptoms for at Least 50% of the Time | Responders were participants that met both of the following criteria on the same week for at least 50% of time on study: 1) average of daily pain scores over the past week improved by ≥30% compared with baseline average in pain score, 2) ≥50% reduction in the number of days over the past week with a BSS score ≥5 compared with Baseline. Participants must also have had at least 5/7 days diary entry to be considered a responder for that week. Abdominal pain was assessed on an 11-point scale where a score of 0=no pain to 10=worst pain imaginable. Stool consistency was assessed using the BSS 7-point scale where: 1=separate hard lumps to 7=watery with no solid pieces. Response rates (percentage of participants) are based on model estimates from the logistic regression. | ITT Analysis Set; Subjects were included in the interval of Weeks 1-4, Weeks 5-8, or Weeks 9-12 if they received at least 1 dose of study medication within that interval. | Posted | Number | percentage of participants | Baseline (Week Prior to Randomization) to Weeks 1-12 |
|
First dose of study drug and up to and including 7 days after date of the last dose of study drug (Up to 114 days)
Safety population: all patients enrolled who received at least 1 dose of study drug. Nine patients were identified as having been randomized more than once in the study, enrolling at a second (or third) site after discontinuation from the first site. All available data for each patient was included in the Safety Analysis Set and was analyzed according to the highest dose level of treatment received.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. | 1 | 159 | 25 | 159 | ||
| EG001 | Eluxadoline 5 mg | Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks. | 1 | 105 | 20 | 105 | ||
| EG002 | Eluxadoline 25 mg | Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. | 3 | 170 | 34 | 170 | ||
| EG003 | Eluxadoline 100 mg | Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks. | 1 | 165 | 27 | 165 | ||
| EG004 | Eluxadoline 200 mg | Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. | 3 | 172 | 43 | 172 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anxiety | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pancreatitis | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Noncardiac chest pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Alcoholic pancreatitis | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Major depression | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Affective disorder | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pancreatitis acute | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Appendicitis perforated | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
|
All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Therapeutic Area Head | Allergan | 714-246-4500 | clinicaltrials@allergan.com |
| ID | Term |
|---|---|
| D043183 | Irritable Bowel Syndrome |
| D003108 | Colonic Diseases |
| D003109 | Colonic Diseases, Functional |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D007410 | Intestinal Diseases |
| D003112 | Colonic Pseudo-Obstruction |
| D003967 | Diarrhea |
| D012817 | Signs and Symptoms, Digestive |
| ID | Term |
|---|---|
| D007418 | Intestinal Pseudo-Obstruction |
| D045823 | Ileus |
| D007415 | Intestinal Obstruction |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C583636 | eluxadoline |
Not provided
Not provided
Not provided
|
|
| 26 to 35 years |
|
|
| 36 to 45 years |
|
|
| 46 to 55 years |
|
|
| 56 to 65 years |
|
|
|
|
| Black or African American |
|
|
| Asian |
|
|
| American Indian or Alaska Native |
|
|
| Native Hawaiian or Other Pacific Islander |
|
|
| Other |
|
|
|
| Not Hispanic or Latino |
|
|
|
|
|
| Odds Ratio (OR) |
| 2.383 |
| 2-Sided |
| 95 |
| 1.036 |
| 5.478 |
| Superiority or Other (legacy) |
| ANCOVA | 0.090 | Odds Ratio (OR) | 2.079 | 2-Sided | 95 | 0.893 | 4.842 | Superiority or Other (legacy) |
| ANCOVA | 0.015 | Odds Ratio (OR) | 2.797 | 2-Sided | 95 | 1.227 | 6.376 | Superiority or Other (legacy) |
Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. |
| OG002 | Eluxadoline 100 mg | Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks. |
| OG003 | Eluxadoline 200 mg | Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. |
| OG004 | Placebo | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. |
|
|
|
Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. |
| OG004 | Placebo | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. |
|
|
Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. |
| OG004 | Placebo | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. |
|
|
Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. |
| OG004 | Placebo | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. |
|
|
| OG002 |
| Eluxadoline 100 mg |
Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks. |
| OG003 | Eluxadoline 200 mg | Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks. |
| OG004 | Placebo | Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|